From: Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
 | Change to aromatase inhibitors | |
---|---|---|
 | Unadjusted | Adjusteda |
Characteristics | OR (95% CI) P -value | OR (95% CI) P -value |
Age | 1.03 (0.98, 1.08) 0.23 | 1.02 (0.95, 1.10) 0.50 |
Breast cancer type | Â | Â |
   Invasive breast cancer | - | - |
   Ductal carcinoma in situ (DCIS) | 1.07 (0.32, 3.48) 0.90 | 1.33 (0.34, 5.11) 0.67 |
   Lobular carcinoma in situ (LCIS) | 0.82 (0.09, 6.76) 0.85 | 0.44 (0.03, 5.59) 0.53 |
Post-menopausal status | 1.54 (0.51, 4.62) 0.43 | 1.78 (0.35, 9.08) 0.48 |
Report of any tamoxifen side effects (yes) | 1.09 (0.34, 3.50) 0.87 | 0.61 (0.16, 2.31) 0.47 |
CYP2D6 phenotype | Â | Â |
   UM/EMb | - | - |
   IM | 0.56 (0.07, 4.59) 0.59 | 0.38 (0.04, 3.38) 0.38 |
   PM | 15.08 (4.26, 53.33) 0.0001 | 22.85 (5.28, 98.74) 0.0001 |
Previous knowledge of CYP2D6 testing (yes) | 0.88 (0.33, 2.38) 0.81 | 0.91 (0.29, 2.84) 0.87 |
Referred by physician or nurse (yes) | 0.60 (0.20, 1.81) 0.37 | 0.36 (0.09, 1.37) 0.13 |
Very interested in CYP2D6 testing before attending the educational session (versus somewhat and not really interested) | 1.77 (0.49, 6.38) 0.38 | 3.01 (0.66, 13.65) 0.15 |